Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Is Cannabis Neuroprotective in Ageing Brains in Dementia? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As research into dementia continues, scientists are exploring whether cannabis compounds such as THC and CBD might help protect ageing brain cells from damage, a concept known as neuroprotection. While laboratory evidence suggests cannabinoids could have protective effects against inflammation and oxidative stress, current human data remain limited, and cannabis is not yet recommended for preventing or treating dementia. 

Can medical cannabis be accessed legally for women’s health?

How Cannabis Might Protect the Brain 

The brain’s endocannabinoid system plays a role in regulating inflammation, blood flow, and neural communication, all critical in ageing and dementia. Cannabinoid receptors (CB1 and CB2) are found throughout the brain, and their activation influences how neurons respond to stress and inflammation. 

According to a BMJ 2022 review, both THC and CBD show potential in laboratory studies to reduce neuroinflammation and oxidative stress, which are key drivers of Alzheimer’s and other dementias. Preclinical findings also suggest CBD may help regulate abnormal protein build-up, such as beta-amyloid and tau, although evidence in humans is still lacking. 

What The Evidence Says 

Animal studies and cell-based experiments indicate that cannabinoids can reduce inflammatory cytokines and promote cell survival under stress. However, human studies are sparse. The NICE dementia guideline (NG97) and the NICE cannabis-based medicinal products guidance (NG144) currently make no recommendation for cannabis in dementia prevention or cognitive protection. 

A 2024 systematic review concluded that while CBD and THC show promise as neuroprotective agents in early-stage research, clinical evidence remains too weak to support therapeutic use. Ongoing trials, such as the UK’s STAND project, aim to clarify whether these findings translate into measurable cognitive benefits. 

Clinical Bottom Line 

  • THC and CBD show neuroprotective effects in laboratory and animal studies. 
  • Human evidence for neuroprotection in dementia remains limited and inconclusive. 
  • NICE and NHS do not recommend cannabis for preventing or slowing cognitive decline. 
  • More clinical trials are needed to determine long-term safety and cognitive outcomes. 

Educational Context: AlleviMed 

AlleviMed offers educational resources about the regulation and clinical frameworks for medical cannabis in the UK. It explains how cannabis-based medicines are assessed by the MHRA and licensed for specific medical conditions, not for dementia or neuroprotection. Its materials emphasise evidence-based understanding and legal access pathways. 

Takeaway 

Cannabis compounds have shown intriguing neuroprotective properties in laboratory research, particularly in reducing inflammation and oxidative stress. However, current human evidence does not confirm these benefits in dementia. According to NICE and NHS guidance, cannabis-based treatments are not approved for preventing cognitive decline. Ongoing studies may reveal more about whether cannabinoids can truly support brain health in ageing, but for now, medical experts recommend caution and further research. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories